The post XRP price slips: Why is the altcoin stuck below $2? appeared on BitcoinEthereumNews.com. This week has been crucial for the altcoin market. With macro The post XRP price slips: Why is the altcoin stuck below $2? appeared on BitcoinEthereumNews.com. This week has been crucial for the altcoin market. With macro

XRP price slips: Why is the altcoin stuck below $2?

3 min read

This week has been crucial for the altcoin market.

With macro FUD still lingering around the government shutdown, and the first FOMC meeting of 2026 signaling a pullback on rate cuts, it seems investors are finally rotating capital into alternative crypto assets.

Ripple [XRP] is following the flow. On the weekly chart, it popped 2.13% from the $1.70–$1.80 band, a zone it hasn’t broken since the 2024 election, clearly marking a solid floor for dip buyers to step in.

Source: TradingView (XRP/USDT)

Supporting this move, the Altcoin Season Index is up 10 points from its mid-January low. Meanwhile, Bitcoin dominance [BTC.D] is testing resistance at 60%, setting up a textbook rotational setup.

All in all, macro FUD plus rotational flows, combined with XRP’s historically strong floor, paint a bullish picture. XRP’s Long/Short ratio at 3.3 as of writing showed the crowd was skewed toward longs, adding weight to the bullish case.

That said, the structure still looks weak. Despite the bullish signals, XRP has printed four lower lows since the late-July high at $3.65, with the latest leg down dragging price back to the post-election-rally zone.

Bottom line? More HODLers are getting pushed underwater.

XRP sees accumulation, but reversal remains elusive

Ripple is putting investor conviction to the test.

On the institutional side, weekly net inflows across XRP ETFs came in at $23 million, while smart money looks to be re-accumulating, with 42+ wallets holding 1 million+ XRP reappearing on-chain.

Against that setup, XRP’s 2.11% weekly bounce looks less like a random move and more like strategic accumulation. Taken together, this helps form a base that could rebuild conviction among underwater HODLers.

Source: TradingView (XRP/USDT)

That said, this isn’t a trend reversal yet. 

As mentioned earlier, macro FUD is still in play, and while rotation back into altcoins plus solid on-chain accumulation could fuel near-term upside, the risk of capitulation stays on the table if key levels don’t flip.

On the chart, XRP needs to clear the $2.15 ceiling, a level that capped the late-December rally. If it fails again, price risks slipping into a loop, putting the $1.80 support back under pressure. Until then, the bias stays bearish.


Final Thoughts

  • Ripple’s weekly bounce, strong floor, and long/short ratio point to renewed conviction despite macro FUD.
  • Four lower lows since July, $2.15 ceiling resistance, and $1.80 support under pressure keep the bias bearish.
Next: Solana processes 40% of L1 throughput amid memecoin boom – Explained

Source: https://ambcrypto.com/xrp-price-slips-why-is-the-altcoin-stuck-below-2/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Bitcoin ETFs Outpace Ethereum With $2.9B Weekly Surge

Bitcoin ETFs Outpace Ethereum With $2.9B Weekly Surge

The surge follows a difficult August, when investors pulled out more than $750 million while rotating capital into Ethereum-focused funds. […] The post Bitcoin ETFs Outpace Ethereum With $2.9B Weekly Surge appeared first on Coindoo.
Share
Coindoo2025/09/18 01:15
CME Group to launch options on XRP and SOL futures

CME Group to launch options on XRP and SOL futures

The post CME Group to launch options on XRP and SOL futures appeared on BitcoinEthereumNews.com. CME Group will offer options based on the derivative markets on Solana (SOL) and XRP. The new markets will open on October 13, after regulatory approval.  CME Group will expand its crypto products with options on the futures markets of Solana (SOL) and XRP. The futures market will start on October 13, after regulatory review and approval.  The options will allow the trading of MicroSol, XRP, and MicroXRP futures, with expiry dates available every business day, monthly, and quarterly. The new products will be added to the existing BTC and ETH options markets. ‘The launch of these options contracts builds on the significant growth and increasing liquidity we have seen across our suite of Solana and XRP futures,’ said Giovanni Vicioso, CME Group Global Head of Cryptocurrency Products. The options contracts will have two main sizes, tracking the futures contracts. The new market will be suitable for sophisticated institutional traders, as well as active individual traders. The addition of options markets singles out XRP and SOL as liquid enough to offer the potential to bet on a market direction.  The options on futures arrive a few months after the launch of SOL futures. Both SOL and XRP had peak volumes in August, though XRP activity has slowed down in September. XRP and SOL options to tap both institutions and active traders Crypto options are one of the indicators of market attitudes, with XRP and SOL receiving a new way to gauge sentiment. The contracts will be supported by the Cumberland team.  ‘As one of the biggest liquidity providers in the ecosystem, the Cumberland team is excited to support CME Group’s continued expansion of crypto offerings,’ said Roman Makarov, Head of Cumberland Options Trading at DRW. ‘The launch of options on Solana and XRP futures is the latest example of the…
Share
BitcoinEthereumNews2025/09/18 00:56
The FDA Is Trying To Make Corporate Free Speech Situational

The FDA Is Trying To Make Corporate Free Speech Situational

The post The FDA Is Trying To Make Corporate Free Speech Situational appeared on BitcoinEthereumNews.com. BENSENVILLE, ILLINOIS – SEPTEMBER 10: Flanked by U.S. Attorney General Pam Bondi (rear), and FDA Commissioner Marty Makary (R), Secretary of Health and Human Services Robert F. Kennedy Jr. speaks to the press outside Midwest Distribution after it was raided by federal agents on September 10, 2025 in Bensenville, Illinois. According to the company, various e-liquids were seized in the raid. (Photo by Scott Olson/Getty Images) Getty Images While running for President in 2008, Barack Obama famously chanted “Yes we can.” Love or hate his political views, Obama’s politics were quite effective. He was asking voters to think big, to envision a much better future. Advertisers no doubt approved. That’s because ads routinely evoke things not as they are, but as they could be. Gyms and exercise equipment companies don’t promote their locations and equipment with flabby, lumbering people, rather their ads show fit, upright, energetic individuals. A look ahead. Restaurants do the same with ads showing happy people enjoying impressively put together plates of food. Conversely, ads meant to convince smokers to quit have not infrequently shown the worst of the worst future downsides of the habit. The nature of advertising comes to mind as FDA commissioner Marty Makary puzzlingly brags that “The Trump Administration Is Taking On Big Pharma” in the New York Times. Makary laments pharmaceutical ads that “are filled with dancing patients, glowing smiles and catch jingles that drown out the fine print.” Not explained is whether Makary would be happier if drug companies placed ads with immobile patients, frowns, and funereal music. Seriously, what does he expect? Does he want drug companies to commit billions to drug development to accompany their achievements with imagery defined by misery? Has Makary stopped to contemplate the myriad shareholders lawsuits drugmakers would face if, upon risking staggering sums meant…
Share
BitcoinEthereumNews2025/09/18 06:29